Business Acquisition - Schedule of Fair Value of Consideration Transferred (Details) |
Jan. 08, 2019
USD ($)
$ / shares
shares
|
|---|---|
| Business Combinations [Abstract] | |
| Common shares issued and outstanding | shares | 24,717,270 |
| Common shares reserved for issuance upon conversion of the outstanding Series B Preferred Stock | shares | 2,312,500 |
| Total Common shares | shares | 27,029,770 |
| Closing price per share of MedoveX Common stock on January 8, 2019 | $ / shares | $ 0.40 |
| Value of common shares | $ 10,811,908 |
| Fair value of outstanding warrants and options | 2,220,000 |
| Cash consideration to RMS | (350,000) |
| Total consideration | $ 12,681,908 |
| X | ||||||||||
- Definition Business acquisition common shares issued and outstanding. No definition available.
|
| X | ||||||||||
- Definition Business acquisition common shares reserved for issuance upon conversion of outstanding. No definition available.
|
| X | ||||||||||
- Definition Business acquisition fair value of outstanding warrants and options. No definition available.
|
| X | ||||||||||
- Definition Business acquisition total number of common shares. No definition available.
|
| X | ||||||||||
- Definition Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|